CMO Gallus taps Xcellerex for single-use capacity

Fledgling contract manufacturer Gallus Biopharmaceuticals sees something it likes in Xcellerex single-use technology--quick capacity expansion. The two companies agreed this week to a multi-piece deal that will equip Gallus with not just the means for quick manufacturing capacity expansion, but also single-use gear for drug development work.

Gallus had acquired J&J Centocor's FDA-approved, commercially certified biologics manufacturing plant in St. Louis, which makes Remicade and Stelara. The CMO is expanding the facility for capacity, the addition of a clinical services suite and the expansion of an existing development lab. The Xcellerex deal marks Gallus's first equipment purchase.

The company says it will invest $20 million on the facility. It plans to eventually add 160 employees to the 160 already employed there. The average salary at Gallus is reportedly $88,500.

Gallus apparently walked into the Xcellerex showroom presold on the FlexFactory platform and components. In addition to single-use XDR bioreactors for commercial manufacturing capacity expansion, the CMO ordered small-scale (10-liter) bioreactors for its development lab. It also ordered a turnkey FlexFactory cGMP manufacturing line with XDR single-use bioreactors to 2,000 liters for clinical trial supply production.

- see the Gallus release
- here's the story

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.